Lueangarun Suparuj, Visutjindaporn Poom, Parcharoen Yardnapar, Jamparuang Pollawat, Tempark Therdpong
Drs. Lueangarun and Visutjindaporn are with the Division of Dermatology, Chulabhorn International College of Medicine, Thammasat University, in Pathum Thani, Thailand.
Dr. Parcharoen is with the Chulabhorn International College of Medicine, Thammasat University in Pathum Thani, Thailand.
J Clin Aesthet Dermatol. 2021 Nov;14(11):E64-E75.
Low-level light/laser therapy (LLLT) can potentially stimulate hair growth in pattern hair loss (PHL), with many available home-use LLLT devices of different designs and technology on the market. However, not all devices are cleared by the United States (US) Food and Drug Administration (FDA), with very few studies to support their efficacy.
This systematic review and meta-analysis aimed to investigate the effectiveness of FDA-approved LLLT devices for PHL treatment.
We included articles related to FDA-approved home-use LLLT devices on PubMed and Medline, using the FDA 510(K) Premarket Notification database and the systematic search of articles up to January 2020. The standardized mean difference (SMD) for the changes of hair density treated by LLLT versus sham devices was analyzed.
Only 32 home-use LLLT devices have been approved by the FDA as of January 2020. The meta-analysis comprised seven double-blinded, randomized, controlled trials. The overall quantitative analysis yielded a significant increase in hair density in those treated by LLLT versus sham groups (SMD: 1.27, 95% confidence interval [CI]: 0.993-1.639). The subgroup analysis demonstrated the increased hair growth in male and female subjects with both comb- and helmet-type devices. There were significant LLLT sources in the LDs alone (SMD: 1.52, 95% CI: 1.16-1.88) and the LDs combination (SMD: 0.85, 95% CI: 0.55-1.16) (=0.043).
LLLT is potentially effective for PHL treatment. Nonetheless, the long-term follow-up study in patients with severe PHL with combined standard treatment and comparison between LLLT devices and energy sources is recommended.
低能量光/激光疗法(LLLT)可能会刺激雄激素性脱发(PHL)患者的头发生长,市场上有许多不同设计和技术的家用LLLT设备。然而,并非所有设备都获得了美国食品药品监督管理局(FDA)的批准,支持其疗效的研究也很少。
本系统评价和荟萃分析旨在研究FDA批准的LLLT设备治疗PHL的有效性。
我们在PubMed和Medline上检索了与FDA批准的家用LLLT设备相关的文章,使用FDA 510(K)上市前通知数据库,并对截至2020年1月的文章进行系统检索。分析了LLLT治疗组与假治疗组头发密度变化的标准化平均差(SMD)。
截至2020年1月,只有32种家用LLLT设备获得了FDA的批准。荟萃分析包括7项双盲、随机、对照试验。总体定量分析显示,LLLT治疗组的头发密度显著高于假治疗组(SMD:1.27,95%置信区间[CI]:0.993-1.639)。亚组分析表明,使用梳子型和头盔型设备的男性和女性受试者的头发生长均有所增加。仅低能量激光单独使用(SMD:1.52,95%CI:1.16-1.8)和低能量激光联合使用(SMD:0.85,95%CI:0.55-1.16)时均有显著的LLLT光源(P=0.043)。
LLLT对PHL治疗可能有效。尽管如此,建议对重度PHL患者进行联合标准治疗的长期随访研究,并比较LLLT设备和能量来源。